Close Menu

Note: This story has been updated with information from the company's earnings call.

NEW YORK – Meridian Bioscience reported on Friday that its fiscal first quarter revenues increased 96 percent year over year due to the firm's COVID-19 products.

For the three months ended Dec. 31, 2020 the firm reported revenues of $92.9 million, up from $47.4 million a year ago. Meridian beat the average Wall Street estimate of $83.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.